株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

B型肝炎:パイプライン製品の分析

Hepatitis B - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232823
出版日 ページ情報 英文 389 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
B型肝炎:パイプライン製品の分析 Hepatitis B - Pipeline Review, H2 2016
出版日: 2016年11月30日 ページ情報: 英文 389 Pages
概要

B型肝炎は、命を脅かす危険性がある肝臓の感染症です。B型肝炎ウイルスは、黄疸、暗色尿、重度の倦怠感、悪心、嘔吐、腹痛を伴う急性疾患の原因となることがあります。B型肝炎に罹患するリスク因子としては、老齢化、重度の腎臓病、血友病、注射針の使いまわし、B型肝炎に感染している母親からの誕生などが挙げられます。抗ウイルス剤等で治療します。

当レポートでは、B型肝炎治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

B型肝炎の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

B型肝炎:企業で開発中の治療薬

B型肝炎:大学/機関で研究中の治療薬

B型肝炎:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

B型肝炎:企業で開発中の製品

B型肝炎:大学/機関で研究中の製品

B型肝炎の治療薬開発に従事している企業

B型肝炎:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

B型肝炎:最近のパイプライン動向

B型肝炎:休止中のプロジェクト

B型肝炎:開発が中止された製品

B型肝炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8742IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Pipeline Review, H2 2016, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 10, 24, 18, 3, 58, 33 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 7 and 6 molecules, respectively.Hepatitis B.

Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 7
  • Hepatitis B Overview 8
  • Therapeutics Development 9
  • Hepatitis B - Therapeutics under Development by Companies 11
  • Hepatitis B - Therapeutics under Investigation by Universities/Institutes 19
  • Hepatitis B - Pipeline Products Glance 20
  • Hepatitis B - Products under Development by Companies 24
  • Hepatitis B - Products under Investigation by Universities/Institutes 33
  • Hepatitis B - Companies Involved in Therapeutics Development 34
  • Hepatitis B - Therapeutics Assessment 121
  • Drug Profiles 133
  • Hepatitis B - Dormant Projects 345
  • Hepatitis B - Discontinued Products 357
  • Hepatitis B - Product Development Milestones 358
  • Appendix 369

List of Tables

  • Number of Products under Development for Hepatitis B, H2 2016 27
  • Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2016 28
  • Number of Products under Development by Companies, H2 2016 30
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 31
  • Number of Products under Development by Companies, H2 2016 (Contd..2) 32
  • Number of Products under Development by Companies, H2 2016 (Contd..3) 33
  • Number of Products under Development by Companies, H2 2016 (Contd..4) 34
  • Number of Products under Development by Companies, H2 2016 (Contd..5) 35
  • Number of Products under Development by Companies, H2 2016 (Contd..6) 36
  • Number of Products under Investigation by Universities/Institutes, H2 2016 37
  • Comparative Analysis by Late Stage Development, H2 2016 38
  • Comparative Analysis by Clinical Stage Development, H2 2016 39
  • Comparative Analysis by Early Stage Development, H2 2016 40
  • Comparative Analysis by Unknown Stage Development, H2 2016 41
  • Products under Development by Companies, H2 2016 42
  • Products under Development by Companies, H2 2016 (Contd..1) 43
  • Products under Development by Companies, H2 2016 (Contd..2) 44
  • Products under Development by Companies, H2 2016 (Contd..3) 45
  • Products under Development by Companies, H2 2016 (Contd..4) 46
  • Products under Development by Companies, H2 2016 (Contd..5) 47
  • Products under Development by Companies, H2 2016 (Contd..6) 48
  • Products under Development by Companies, H2 2016 (Contd..7) 49
  • Products under Development by Companies, H2 2016 (Contd..8) 50
  • Products under Investigation by Universities/Institutes, H2 2016 51
  • Hepatitis B - Pipeline by Abivax SA, H2 2016 52
  • Hepatitis B - Pipeline by AiCuris GmbH & Co KG, H2 2016 53
  • Hepatitis B - Pipeline by AIMM Therapeutics BV, H2 2016 54
  • Hepatitis B - Pipeline by Akshaya Bio Inc, H2 2016 55
  • Hepatitis B - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 56
  • Hepatitis B - Pipeline by AlphaMab Co., Ltd, H2 2016 57
  • Hepatitis B - Pipeline by Altimmune Inc, H2 2016 58
  • Hepatitis B - Pipeline by Altravax Inc, H2 2016 59
  • Hepatitis B - Pipeline by Amarna Therapeutics BV, H2 2016 60
  • Hepatitis B - Pipeline by Arbutus Biopharma Corp, H2 2016 61
  • Hepatitis B - Pipeline by Arcturus Therapeutics Inc, H2 2016 62
  • Hepatitis B - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 63
  • Hepatitis B - Pipeline by Assembly Biosciences Inc, H2 2016 64
  • Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016 65
  • Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 66
  • Hepatitis B - Pipeline by Benitec Biopharma Ltd, H2 2016 67
  • Hepatitis B - Pipeline by Biogenomics Limited, H2 2016 68
  • Hepatitis B - Pipeline by Biological E Ltd, H2 2016 69
  • Hepatitis B - Pipeline by BioStar Pharmaceuticals Inc, H2 2016 70
  • Hepatitis B - Pipeline by Bolder Biotechnology Inc, H2 2016 71
  • Hepatitis B - Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2016 72
  • Hepatitis B - Pipeline by Bukwang PharmCo Ltd, H2 2016 73
  • Hepatitis B - Pipeline by CaroGen Corp, H2 2016 74
  • Hepatitis B - Pipeline by Celltrion Inc, H2 2016 75
  • Hepatitis B - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 76
  • Hepatitis B - Pipeline by Chromis Therapeutics, Inc., H2 2016 77
  • Hepatitis B - Pipeline by ChronTech Pharma AB, H2 2016 78
  • Hepatitis B - Pipeline by Cocrystal Pharma Inc, H2 2016 79
  • Hepatitis B - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 80
  • Hepatitis B - Pipeline by CyTuVax BV, H2 2016 81
  • Hepatitis B - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 82
  • Hepatitis B - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 83
  • Hepatitis B - Pipeline by Dynavax Technologies Corp, H2 2016 84
  • Hepatitis B - Pipeline by Ensemble Therapeutics Corp, H2 2016 85
  • Hepatitis B - Pipeline by eTheRNA Immunotherapies NV, H2 2016 86
  • Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 87
  • Hepatitis B - Pipeline by GeneCure LLC, H2 2016 88
  • Hepatitis B - Pipeline by GeoVax Labs Inc, H2 2016 89
  • Hepatitis B - Pipeline by Gilead Sciences Inc, H2 2016 90
  • Hepatitis B - Pipeline by GlaxoSmithKline Plc, H2 2016 91
  • Hepatitis B - Pipeline by Green Cross Corp, H2 2016 92
  • Hepatitis B - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 93
  • Hepatitis B - Pipeline by HEC Pharm Co., Ltd., H2 2016 94
  • Hepatitis B - Pipeline by Humabs BioMed SA, H2 2016 95
  • Hepatitis B - Pipeline by Huons Co Ltd, H2 2016 96
  • Hepatitis B - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2016 97
  • Hepatitis B - Pipeline by Immunotope Inc, H2 2016 98
  • Hepatitis B - Pipeline by Indian Immunologicals Ltd, H2 2016 99
  • Hepatitis B - Pipeline by Intellia Therapeutics Inc, H2 2016 100
  • Hepatitis B - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 101
  • Hepatitis B - Pipeline by ISA Pharmaceuticals BV, H2 2016 102
  • Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016 103
  • Hepatitis B - Pipeline by Johnson & Johnson, H2 2016 104
  • Hepatitis B - Pipeline by Kineta Inc, H2 2016 105
  • Hepatitis B - Pipeline by Lakewood-Amedex Inc, H2 2016 106
  • Hepatitis B - Pipeline by Leukocare AG, H2 2016 107
  • Hepatitis B - Pipeline by LG Life Science LTD, H2 2016 108
  • Hepatitis B - Pipeline by Ligand Pharmaceuticals Inc, H2 2016 109
  • Hepatitis B - Pipeline by Mucosis BV, H2 2016 110
  • Hepatitis B - Pipeline by MultiCell Technologies Inc, H2 2016 111
  • Hepatitis B - Pipeline by Oncolys BioPharma Inc, H2 2016 112
  • Hepatitis B - Pipeline by Panacea Biotec Ltd, H2 2016 113
  • Hepatitis B - Pipeline by Pfenex Inc, H2 2016 114
  • Hepatitis B - Pipeline by PharmaEssentia Corp, H2 2016 115
  • Hepatitis B - Pipeline by Poxel SA, H2 2016 116
  • Hepatitis B - Pipeline by Profarma, H2 2016 117
  • Hepatitis B - Pipeline by Profectus BioSciences Inc, H2 2016 118
  • Hepatitis B - Pipeline by Redx Pharma Plc, H2 2016 119
  • Hepatitis B - Pipeline by REPLICor Inc, H2 2016 120
  • Hepatitis B - Pipeline by Rodos BioTarget GmbH, H2 2016 121
  • Hepatitis B - Pipeline by Samjin Pharmaceutical Co Ltd, H2 2016 122
  • Hepatitis B - Pipeline by Sanofi Pasteur SA, H2 2016 123
  • Hepatitis B - Pipeline by Shantha Biotechnics Ltd, H2 2016 124
  • Hepatitis B - Pipeline by Sinovac Biotech Ltd, H2 2016 125
  • Hepatitis B - Pipeline by Spring Bank Pharmaceuticals Inc, H2 2016 126
  • Hepatitis B - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H2 2016 127
  • Hepatitis B - Pipeline by TCM Biotech International Corp, H2 2016 128
  • Hepatitis B - Pipeline by TetraLogic Pharmaceuticals, H2 2016 129
  • Hepatitis B - Pipeline by TGV-Laboratories, H2 2016 130
  • Hepatitis B - Pipeline by Theravectys SA, H2 2016 131
  • Hepatitis B - Pipeline by Tomegavax Inc, H2 2016 132
  • Hepatitis B - Pipeline by Transgene SA, H2 2016 133
  • Hepatitis B - Pipeline by Vaxine Pty Ltd, H2 2016 134
  • Hepatitis B - Pipeline by VBI Vaccines Inc, H2 2016 135
  • Hepatitis B - Pipeline by Viriom Ltd, H2 2016 136
  • Hepatitis B - Pipeline by VLP Biotech Inc, H2 2016 137
  • Hepatitis B - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 138
  • Assessment by Monotherapy Products, H2 2016 139
  • Assessment by Combination Products, H2 2016 140
  • Number of Products by Stage and Target, H2 2016 142
  • Number of Products by Stage and Mechanism of Action, H2 2016 145
  • Number of Products by Stage and Route of Administration, H2 2016 148
  • Number of Products by Stage and Molecule Type, H2 2016 150
  • Hepatitis B - Dormant Projects, H2 2016 363
  • Hepatitis B - Dormant Projects (Contd..1), H2 2016 364
  • Hepatitis B - Dormant Projects (Contd..2), H2 2016 365
  • Hepatitis B - Dormant Projects (Contd..3), H2 2016 366
  • Hepatitis B - Dormant Projects (Contd..4), H2 2016 367
  • Hepatitis B - Dormant Projects (Contd..5), H2 2016 368
  • Hepatitis B - Dormant Projects (Contd..6), H2 2016 369
  • Hepatitis B - Dormant Projects (Contd..7), H2 2016 370
  • Hepatitis B - Dormant Projects (Contd..8), H2 2016 371
  • Hepatitis B - Dormant Projects (Contd..9), H2 2016 372
  • Hepatitis B - Dormant Projects (Contd..10), H2 2016 373
  • Hepatitis B - Dormant Projects (Contd..11), H2 2016 374
  • Hepatitis B - Discontinued Products, H2 2016 375

List of Figures

  • Number of Products under Development for Hepatitis B, H2 2016 27
  • Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2016 28
  • Number of Products under Development by Companies, H2 2016 29
  • Number of Products under Investigation by Universities/Institutes, H2 2016 37
  • Comparative Analysis by Late Stage Development, H2 2016 38
  • Comparative Analysis by Clinical Stage Development, H2 2016 39
  • Comparative Analysis by Early Stage Products, H2 2016 40
  • Assessment by Monotherapy Products, H2 2016 139
  • Assessment by Combination Products, H2 2016 140
  • Number of Products by Top 10 Targets, H2 2016 141
  • Number of Products by Stage and Top 10 Targets, H2 2016 141
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 144
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 144
  • Number of Products by Routes of Administration, H2 2016 147
  • Number of Products by Stage and Routes of Administration, H2 2016 147
  • Number of Products by Top 10 Molecule Types, H2 2016 149
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016 149
Back to Top